Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-27705
Zihler, A; Le Blay, G; de Wouters, T; Lacroix, C; Braegger, C; Lehner, A; Tischler, P; Rattei, T; Hächler, H; Stephan, R (2009). In vitro inhibition activity of different bacteriocinproducing Escherichia coli against Salmonella strains isolated from clinical cases. Letters in Applied Microbiology, 49(1):31-38.
|PDF - Registered users only|
AIMS: To compare in vitro the inhibitory activity of four bacteriocin-producing Escherichia coli to a well-characterized panel of Salmonella strains, recently isolated from clinical cases in Switzerland. METHODS AND RESULTS: A panel of 68 nontyphoidal Salmonella strains was characterized by pulsed-field gel electrophoresis analysis and susceptibility to antibiotics. The majority of tested strains were genetically different, with 40% resistant to at least one antibiotic. E. coli Mcc24 showed highest in vitro activity against Salmonella (100%, microcin 24), followed by E. coli L1000 (94%, microcin B17), E. coli 53 (49%, colicin H) and E. coli 52 (21%, colicin G) as revealed using a cross-streak activity assay. CONCLUSIONS: Escherichia coli Mcc24, a genetically modified organism producing microcin 24, and E. coli L1000, a natural strain isolated from human faeces carrying the mcb-operon for microcin B17-production, were the most effective strains in inhibiting in vitro both antibiotic resistant and sensitive Salmonella isolates. SIGNIFICANCE AND IMPACT OF THE STUDY: Due to an increasing prevalence of antibiotic resistant Salmonella strains, alternative strategies to fight these foodborne pathogens are needed. E. coli L1000 appears to be a promising candidate in view of developing biotechnological alternatives to antibiotics against Salmonella infections.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic|
|DDC:||610 Medicine & health|
|Deposited On:||20 Jan 2010 16:51|
|Last Modified:||26 Nov 2012 10:34|
|Additional Information:||The definitive version is available at www.blackwell-synergy.com|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page